The precision cardiology market will rise at a compound annual growth rate of 12.8% by the end of this decade to reach a value of USD 2,998.4 million by 2030. The growth of the industry is supported by the decreasing cost of sequencing methods, increasing consciousness of early screening of CVDs, and increasing burden of CVDs.
The service category held a share of about 80%. This has a lot to do with the increasing stress on the acceptance of precision medicine in clinical settings.
Furthermore, factors like unhealthy diet, sedentary lifestyle, obesity, and the increasing population of pre-diabetics and diabetics worldwide, are striking a combinative effect upon the worldwide burden of CVDs, resulting in the increasing precision diagnosis’ services requirement.
The non-blood samples category will grow at a considerable rate by the end of this decade. This has a lot to do with the clinical utilities of non-blood samples, which have been well-established and recognized for directing precision tests.
North America dominated the precision cardiology market in the recent past. This has a lot to do with the existence of major players of the market in the U.S. and the substantial acceptance of cutting-edge products and services in research and clinical settings.
Furthermore, initiatives of the government targeting the association of genetic biomarkers with CVD care have significantly pushed the market in the region.
It is because of the reducing cost of sequencing method, the demand for precision cardiology will continue to increase in the years to come.
No comments:
Post a Comment